Home Topics OMICs miRNA BIOMARKERS FOR DRUG-INDUCED LIVER INJURY miRNA BIOMARKERS FOR DRUG-INDUCED LIVER INJURY March 12, 2009 – Interview with David Galas, Ph.D., Senior Vice President of Strategic Partnerships, Institute for Systems Biology /wp-content/uploads/2018/09/gc254_3_12_2009.mp3 BiomarkersCellular, Molecular and Developmental BiologyComputational biologyDiagnosisDrug-induced liver injuryHepatic injuryMedicine, Diagnosis, and TherapeuticsmiRNA (RNA isoforms)Molecular biologyMolecular biomarkerOrgan injuryRNA biologyRNA biomarkerRNA isoformsSystemic conditionsSystems biologyTechnology and Computational BiologyTrauma and injury Also of Interest 10x Ships First Single Cell GEM-X Assays to Customers StockWatch: Blockbuster Sales Projected for Madrigal MASH Drug Machine Learning Can Spot Tumor-Reactive TCRs, Speed Immunotherapies Gene Activity Study May Lead to Better Therapies for Fibrosis of the Liver Uncovering RNA Splicing’s Cell-Specific Impact on Clonal Blood Disorders with GoT-Splice Lab Space Giant Alexandria Real Estate Navigates AI’s Impact on Biopharma Related Media Carl Icahn States His Case for Change at Illumina on "Close to the Edge" Celebrating DNA Day: An Interview with Eric Green on "The State of Genomics" Celebrating DNA: Matthew Cobb's Reflections on the Double Helix Emerging Markets Collaborate to Succeed in Post-Pandemic World The Sun Sets on AGBT: A Report from the Last Day Spatial, Sequencing, and Sun: A Report from Day 2 of AGBT Related Content 10x Ships First Single Cell GEM-X Assays to Customers StockWatch: Blockbuster Sales Projected for Madrigal MASH Drug Machine Learning Can Spot Tumor-Reactive TCRs, Speed Immunotherapies Gene Activity Study May Lead to Better Therapies for Fibrosis of the Liver